No Data
No Data
Integral Diagnostics Ltd. Sees Shift in Substantial Holdings
Integral Diagnostics' Merger Could Deliver Revenue Synergies -- Market Talk
Integral Diagnostics Target Price Raised 21% to A$3.50/Share by Macquarie>IDX.AU
Internal Diagnostics' Set for Upside to Returns Post Merger With Capitol Health, Jarden Says
Jarden Sticks to Its Buy Rating for Integral Diagnostics Ltd. (IDX)
Jarden Adjusts Integral Diagnostics' Price Target to AU$3.68 From AU$3.72, Keeps at Buy
No Data